Protagonist Therapeutics Inc
PTGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.28B
Close$
$-4.01
102.7% downside
Current Fair Value
102.7% downsideOvervalued by 102.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.28 Billion |
|---|---|
| Enterprise Value | $8.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.05 |
| Beta | 1.79 |
| Outstanding Shares | 65,935,769 |
Return
| Return on Equity | 9.85% |
|---|---|
| Return on Assets | 9.36% |
| Return on Invested Capital | 8.36% |
Valuation & Multiples
| P/E Ratio | 118.49 |
|---|---|
| PEG | -20.85 |
| Price to Sales | 49.6 |
| Price to Book Ratio | 12.4 |
| Enterprise Value to Revenue | 38.4 |
| Enterprise Value to EBIT | 125.22 |
| Enterprise Value to Net Income | 107 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$202.70 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.43
Average shareholder expectationRevenue Estimate
$240.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5935▲ 36.00% |
|---|---|
| Total Calls | 396,100▲ 36.63% |
| Total Puts | 235,100▲ 247.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 128.36%▲ 4.49% |
|---|---|
| Total Invested | $9.41B▲ 13.46% |
| Investors Holding | 357▲ 24.00% |
ESG Score
No data